In two days, the Fifth Health and Development Forum will be held in Zhongshan. The Forum since its inception in 2006, not only to promote the health and health industries are rapidly developing economy, digital thermometer but also witnessed the rapid development of the health industry, Zhongshan course.
According to statistics, more than 10 years after a short period of development, clinical thermometer bio-pharmaceutical companies, Zhongshan few from the original home of more than 130 to the present, hearing aids is occupied 75% market share in the country. National health industry base and the city of South China Modern medicine has attracted two bases Merck Park Place, Germany Gelan Tai, clinical thermometer dozens of well-known pharmaceutical enterprises have settled down.
The sudden emergence of bio-pharmaceutical industry.
According to statistics, in 2009, China's biomedical industry revenue reached 75.3 billion total sales, the profit growth rate of 70%.digital blood pressure monitor The same period, Zhongshan biomedical industry output value of about 150 million.
By comparing this set of data we can see that, after 10 years of development, Zhongshan, from small to large bio-pharmaceutical industry, had become the scale, the proportion getting hit in the country, more and more influential.
Bio-pharmaceutical industry as a focus on creating new, Zhongshan City, a pillar industry in recent years has shown a steady development trend. According to statistics, the city's medical device production and operation of enterprises from 32 in 2001 to more than 130 to the present, hearing aids is occupied 75% market share in the country. In 2009, the biomedical industry, the financial crisis broke the trend, the annual accumulated about 150 billion yuan output value. Currently, the Zhongshan Park Place has attracted Merck, Germany Gelan Tai, Ruishi Hui Ling, Guangdong Kyushu, the U.S. oz, Chile Pharmaceutical Group, more than 50 well-known pharmaceutical enterprises have settled down.
As the province's industrial clusters, Zhongshan one of the highest degree, biological medicine industry from the start along the direction of industrial clusters and the formation of a good research and development, transformation, production and promotion of the industrial chain.
As early as 1994 with the National Science and Technology, Guangdong Provincial People's Government established the National Health Technology Park, to start planning for the implementation of health food, medicine and construction and development of industrial clusters. Today, Zhongshan City, the National Health Technology Park development has begun to take shape. Base master plan to meet U.S. Ft) A, NIH and China SH) A recognized standard, and set up their own drug research institutes and pharmaceutical companies, and South Korea, Hong Kong and other overseas organizations and institutions outside the province a number of enterprises to develop new drugs , there are hundred contains medicines, health products, biological products and medical devices, medical packaging, health-related products, foreign large enterprises, together they created a R & D, clinical trials, new drugs to declare to the supply of raw materials, finished product packaging and then to the industrial chain and marketing system for the pharmaceutical industry.
In addition, Zhongshan City, and in recent years, the city launched the project of South China Modern Traditional Chinese Medicine, established a set of industry, academia, and research in one of the development of Chinese medicine system, the formation of the National Health Technology Park as the main industry, rational layout, complete and perfect at home more competitive outside the pharmaceutical industry gathered in the Highlands.
Frequent positive industry prospects.
National Health Base and the South China city of modern Chinese medicine, like two strong legs support from the biomedical industry in Zhongshan sky, to ensure stable and rapid development of Zhongshan health industry, the cornerstone of its domestic status to the province as well.
It is based on Zhongshan become the size and health industry has a certain competitiveness, "Reform and Development of the Pearl River Delta Plan" will be positioned as the health industry one of the three pillar industries, Zhongshan. According to the "Outline", Zhongshan will focus on the development of "port equipment manufacturing, fine chemicals and health industry base."
Recently, the State Council promulgated the "Regulations on accelerating the development of new industries and development of a strategic decision," one of the elements is the requirement to vigorously improve the level of bio-pharmaceutical industry. "Decision" of the introduction, for the period of rapid development is now Zhongshan biomedical industry is concerned, once again faced with major development opportunities.
China experts say, in addition to the "Decision" requirement to vigorously support the development of bio-pharmaceutical industry, the now undoubtedly the most compelling, "2010-2015 biomedical industry revitalization plan." Biomedical second Five-Year Plan led by the Development and Reform Commission, Ministry of Industry, Ministry of Finance, Ministry of Science and other ministries involved, the focus will be on the development of gene medicines, therapeutic vaccines, small molecule drugs. The new planning for the revitalization of biological pharmaceutical industry, will lead the biomedical industry in China onto a new level.
In response, the industry, Zhongshan biomedical industry itself has a good foundation for development in the country also accounts for a sizeable share of the frequent introduction of favorable policies will undoubtedly further stimulate the rapid development of Zhongshan health industry.
Frequently introduced good policies, but also the health industry to further enhance the rapid development of Zhongshan confidence. According to report, the current health plans to attract a large number of base health care information company located in Zhongshan, the establishment of health and medical information center, set of software development, smart medical device manufacturing, exhibition, e-commerce as one of the industry cluster. Health information is expected within two years of industry output of 20 billion within five years reached 100 billion yuan.
Constrained by the weak development of R & D capabilities.
On the one hand the development of more than 10 years based on the other hand, the stimulation of a variety of good policies, Zhongshan into the bio-pharmaceutical industry is still the fast lane, but the industry, said in an interview, due to autonomous technological innovation mechanism has not yet formed, independent research and development of enterprises, innovation is weak, it will seriously affect the sustainable development of Zhongshan health industry.
Local experts told reporters, independent research and technology, biomedical innovation capability is the basis for enterprise survival and development, despite the Zhongshan municipal government continued to strengthen technological innovation, increase investment in research and development, but the main R & D is government, business For the independent research and development investment is relatively small.
"Just want to sit back and enjoy some SMEs do not attach importance to R & D investment, investment in new drug R & D every year fund sales less than 1% of independent technology innovation mechanism has not yet effective form." The expert said, which makes the lack of many bio-pharmaceutical companies and even no proprietary technology, most of them products of the core technology is introduced, or evolved by the joint venture. Which, according to overseas experience in the development of bio-pharmaceutical industry, the enterprise should be the R & D and innovation.
In addition, although very seriously, Zhongshan City, the development of bio-pharmaceutical industry through the development of recent years has formed a certain amount of scientific and technological personnel, but in general, innovation teams were in short supply. According to related statistics, as of 2009, Zhongshan City, biomedical science and technology personnel in less than 1 million, and AstraZeneca R & D personnel professionals already reached the 1.2 million people.
In addition to bio-pharmaceutical industry scientists, it also requires a lot of specialized biomedical project evaluation, industry cooperation and market bio-pharmaceutical industry expertise, and Jidong medical technology but also understands the complexities of management talent, and Zhongshan City, these specialized personnel and versatile personnel are very lacking. Experts said the lack of human capital severely restricted the biomedical industry, management and innovation, but also affected the biomedical industry, Zhongshan City, the sustainable development.